PTC Therapeutics Raises 2026 Guidance After Strong Q2: $361M Revenue, $2.2B Cash, New Board Member
PTCT sits 78% above its 52-week low of $43.175.
Summary
PTC Therapeutics reported Q2 2026 revenue of $361 million, raised full-year guidance, and swung to profitability. The company also appointed a new board member.
Key Events · Earnings and Guidance · PTCT
-
Q2 Revenue Beats, Profitability Returns
Total revenue of $361 million, including $239 million in product revenue, drove net income of $83.5 million compared to a $64.8 million loss in Q2 2025.
-
Full-Year Guidance Raised
2026 total revenue guidance increased to $1.18–$1.28 billion, with product revenue guidance raised to $850–$950 million from $750–$850 million.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities totaled $2.2 billion as of June 30, 2026, bolstered by a $550 million convertible note offering.
-
Sephience Launch Momentum
Sephience revenue reached $151 million in Q2, with 1,647 patients on commercial therapy worldwide and expanding international contributions.
Analysis · PTCT · Life Sciences
PTC Therapeutics delivered a standout second quarter, with total revenue of $361 million driven by $239 million in product sales. The company raised its full-year 2026 total revenue guidance to $1.18–$1.28 billion and product revenue guidance to $850–$950 million, signaling confidence in the ongoing Sephience launch and pipeline progress. Net income swung to $83.5 million from a loss a year ago, and the cash position strengthened to $2.2 billion following a $550 million convertible note offering. The appointment of former CHRO Hege Sollie-Zetlmayer to the board adds operational depth. This filing materially updates the investment thesis with better-than-expected financials and raised outlook.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $77.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $43.18 to $90.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.